A prospective randomised double-blind, double-dummy, placebo-controlled crossover study to determine whether Glucagon-like peptide-1 (GLP-1) stimulates or suppresses pancreatic exocrine function in health.

Not Applicable

Withdrawn

• Conditions: Hyperglycaemia; Type 2 Diabetes; Critical Illness-induced hyperglycaemia; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12614000815662
• Lead Sponsor: Dr Adam Deane

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-31
• Last Update Posted: 28 June 2021

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Male
• Target Recruitment: 15

Inclusion Criteria

Healthy Male volunteers between the ages of 18-35

Exclusion Criteria

Inability to give informed consent
History of diabetes
History of pancreatitis
Lipase level >210 U/L
Amylase level > 110 U/L
Estimated glomerular filtration rate < 60ml/min
Impared liver function (ALT >55 U/L; Albumin <34g/l, ALP >110 U/L; Bilirubin >25 umol; GGT > 80 U/L)
Haemoglobin <135g/L
HbA1c >6%
Body Mass Index >32kg/m2
Smoking > 10 cigarettes/day
Alcohol consumption >20g/day
Volunteers who have donated blood in the preceding 3 months
Female volunteers of child bearing age
Suffer from any chronic medical conditions such as (but not limited to) heart failure, ischaemic heart disease, chronic lung disease, autonomic dysfunction resulting from any cause active or previously treated malignancy, chronic infections (e.g viral hepatitis and HIV)
Suffered from any acute medical illnesses during the 4 week period before recruitment
Contraindications to any of the drugs used in this study (e.g. known hypersensitivity)
Gallstone(s) visualised on ultrasound at the screening visit.

Study & Design

• Study Type: Interventional
• Study Design: Not specified